Imaginostics
Orlando, US · Delaware corporation
Biotech
Founders & leadership
VA
Valerie Aimee GharagouzlooExecutive Officer, Director, Promoter
CG
Codi GharagouzlooExecutive Officer, Director, Promoter
SH
Scott HogeExecutive Officer
Reported raises · per SEC filings
Form D private placements▶$40KraisedMay 2026 · 1 investors · BiotechnologyRule 506(b)
▶$40KraisedMay 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CODI GHARAGOUZLOOExecutive Officer, Director, Promoter
- VALERIE AIMEE GHARAGOUZLOOExecutive Officer, Director, Promoter
- WILLIAM SCOTT HOGEExecutive Officer
- Amount sold
- $40K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50KraisedApr 2026 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedApr 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott HogeExecutive Officer
- Valerie Aimee GharagouzlooExecutive Officer, Director, Promoter
- Codi GharagouzlooExecutive Officer, Director, Promoter
- Amount sold
- $50K
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedApr 2026 · 75 investors · BiotechnologyRule 506(b)
▶$5.4MraisedApr 2026 · 75 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott ScHogeExecutive Officer
- Valerie Aimee GharagouzlooExecutive Officer, Director, Promoter
- Codi GharagouzlooExecutive Officer, Director, Promoter
- Amount sold
- $5.4M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$725.3KraisedApr 2026 · 1 investors · BiotechnologyRule 506(b)
▶$725.3KraisedApr 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Valerie Aimee GharagouzlooExecutive Officer, Director, Promoter
- Codi GharagouzlooExecutive Officer, Director, Promoter
- Scott HogeExecutive Officer
- Offering amount
- $725.3K
- Amount sold
- $725.3K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$400KraisedApr 2026 · 5 investors · BiotechnologyRule 506(b)
▶$400KraisedApr 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Codi GharagouzlooExecutive Officer, Director, Promoter
- Scott HogeExecutive Officer
- Valerie Aimee GharagouzlooExecutive Officer, Director, Promoter
- Amount sold
- $400K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$516.9KraisedApr 2026 · 18 investors · BiotechnologyRule 506(b)
▶$516.9KraisedApr 2026 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Valerie Aimee GharagouzlooExecutive Officer, Director, Promoter
- Codi GharagouzlooExecutive Officer, Director, Promoter
- Scott HogeExecutive Officer
- Amount sold
- $516.9K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedApr 2026 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedApr 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott HogeExecutive Officer
- Codi GharagouzlooExecutive Officer, Director, Promoter
- Valerie Aimee GharagouzlooExecutive Officer, Director, Promoter
- Amount sold
- $100K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $915.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $436.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.